Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome.

European journal of endocrinology - 1 Dec 2016

Božić-Antić Ivana, Ilić Dušan, Bjekić-Macut Jelica, Bogavac Tamara, Vojnović-Milutinović Danijela, Kastratovic-Kotlica Biljana, Milić Nataša, Stanojlović Olivera, Andrić Zoran, Macut Djuro

Abstract excerpt

OBJECTIVE: There are limited data on cardiometabolic risk factors and the prevalence of metabolic syndrome (MetS) across the different PCOS phenotypes in Caucasian population. Lipid accumulation product (LAP) is a clinical surrogate marker that could be used for evaluation of MetS in clinical practice. The aim of the study was to analyze metabolic characteristics and the ability of LAP to predict MetS in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Disease Susceptibility

Share to Metabolic Syndrome

Share to Phenotype

Share to Polycystic Ovary Syndrome

Share to Young Adult

Source

Identifiers

PMID: 27634940
DOI: 10.1530/EJE-16-0775

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome.PMID 27634940Read ↗

Metabolic syndrome and metabolic risk profile according to polycystic ovary syndrome phenotype.Semantic proximity Read ↗

Metabolic syndrome and its components in different phenotypes of polycystic ovary syndrome.Semantic proximity Read ↗

Metabolic risk in PCOS: phenotype and adiposity impact.Semantic proximity Read ↗

The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers.Semantic proximity Read ↗

Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment.Semantic proximity Read ↗

Lipid Accumulation Product: An Obtainable and Accurate Marker for Predicting Metabolic Syndrome in Kidney Transplant RecipientsSemantic proximity Read ↗

Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.Semantic proximity Read ↗

Cardiometabolic Markers and Serum Amh Levels in Pcos: Can Amh Serve as a Surrogate Cardiometabolic Marker?Semantic proximity Read ↗

Prevalence of metabolic syndrome among women with different PCOS phenotypes - a prospective study.Semantic proximity Read ↗

Cardiometabolic Syndromes and Associated Cardiovascular Risks: A Narrative Review.Semantic proximity Read ↗

Visceral Adiposity Index and Lipid Accumulation Product as Effective Markers of Different Obesity Phenotypes in Korean Adults: A Cross-Sectional AnalysisSemantic proximity Read ↗

Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.